Synmosa Biopharma Cash Flow-to-Debt Ratio
Synmosa Biopharma cash flow-to-debt ratio. Synmosa Biopharma (4114) has a Cash Flow-to-Debt Ratio of 0.05x as of December 2025, meaning its operating cash flow of NT$185.72 Million could theoretically repay 0% of its total liabilities (NT$3.89 Billion) in one year. Check Synmosa Biopharma cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Synmosa Biopharma (2015–2025)
Cash flow-to-debt ratio of Synmosa Biopharma from 2015 to 2025. Historical debt coverage capacity for Synmosa Biopharma across 11 annual periods. Check cash flow reinvestment rate of Synmosa Biopharma to assess the company's total reinvestment commitment from operating cash flow.
Synmosa Biopharma Cash Flow-to-Debt Ratio by Year (2015–2025)
Synmosa Biopharma cash flow-to-debt ratio by year from 2015 to 2025. Year-by-year debt coverage analysis for Synmosa Biopharma. For the full cash flow conversion analysis, see cash efficiency ratio of Synmosa Biopharma.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.11x | NT$411.57 Million | NT$3.89 Billion | ▼ -47.0% |
| 2024 | 0.20x | NT$780.62 Million | NT$3.91 Billion | ▲ +41.6% |
| 2023 | 0.14x | NT$511.93 Million | NT$3.63 Billion | ▲ +2.0% |
| 2022 | 0.14x | NT$630.25 Million | NT$4.55 Billion | ▲ +31.5% |
| 2021 | 0.11x | NT$444.29 Million | NT$4.22 Billion | ▲ +83.0% |
| 2020 | 0.06x | NT$254.40 Million | NT$4.42 Billion | ▲ +602.0% |
| 2019 | -0.01x | NT$-44.88 Million | NT$3.92 Billion | ▼ -319.1% |
| 2018 | 0.01x | NT$16.00 Million | NT$3.06 Billion | ▲ +456.2% |
| 2017 | 0.00x | NT$-5.19 Million | NT$3.54 Billion | ▼ -101.5% |
| 2016 | 0.10x | NT$236.48 Million | NT$2.44 Billion | ▲ +549.1% |
| 2015 | 0.01x | NT$23.60 Million | NT$1.58 Billion | — |